The endoplasmic reticulum (ER) stress response (or unfolded protein response [UPR] ) is a series of well-orchestrated cellular events to restore homeostasis in the perturbed ER. During the UPR, ER-resident molecular chaperones and foldases are induced, and translation is attenuated to reduce the load on the ER (reviewed in references 2, 49, 51, 67, 84, and 88). Unfolded proteins can also be targeted by ubiquitination for degradation by the proteasome, which is termed ER-associated degradation (ERAD) (35, 60, 70) . Apoptosis occurs when all of these remedies have failed (16, 48, 63, 64) . Current studies of the UPR mechanism in mammalian cells have identified three signaling arms represented by three ER membrane-bound proteins, PERK (PKR-like ER kinase) (14) (15) (16) (17) (18) , ATF6␣/␤ (19, 20, 75, 76, 92, 93) , and IRE1 (6, 39, 78, 91) . The activation of PERK by ER stress leads to global translational repression but selective activation of ATF4, whose downstream targets include metabolic genes and apoptosis-related CHOP (14, 26, 41, 55, 66, 80) . ATF6 is an ER membranebound basic-region leucine zipper (bZIP) transcription factor that is activated by the regulated intramembrane proteolysis (RIP) mechanism (5) . When ATF6 cleavage is triggered by ER stress (23, 87, 92, 93) , the N terminus that encodes the transcription activation domain and the bZIP region translocates to the nucleus to activate downstream genes, such as ER chaperone BiP/GRP78 and GRP94, through the ER stress response element (ERSE) (65, 68, 82, 89, 92, 93) . Activated IRE1 initiates spliceosome-independent alternative splicing of XBP1u mRNA, resulting in a potent bZIP transcription factor XBP1s (6, 39, 59, 69, 91) . Like ATF6, XBP1s activates ER chaperone genes via an ERSE (91) , but it also activates transcription through another cis-acting element, unfolded protein response element (UPRE) (82, 90) . The known candidate genes potentially regulated by the UPRE enhancer include HRD1 (29) , Derlins (56) , and EDEM (ER degradation-enhancing ␣-mannosidase-like protein) (50, 90) , all of which are believed to play a role in ERAD. Recent data suggest that ATF6 is also essential for ERAD (85, 86) as ATF6 can bind and activate transcription from the UPRE as a heterodimer with XBP1 (86) .
Luman/CREB3 (44) (also called LZIP [13] ) is the primary member of the CREB3 family. All CREB3 family members appear to play a role in the UPR. Currently, there are four known family members in addition to Luman, including CREB-H/CREB3-like 1 (CREB3L1) (8, 58) , BBF2H7/CREB3L2 (73) , OASIS/CREB3L3 (24) , and CREB4/AIbZIP/Atce1/Tisp40/ CREB3L4 (7, 53, 61, 71, 72) . Besides the well-conserved bZIP region, they all share one unique structural motif-a hydrophobic ER-transmembrane domain C-terminal to the bZIP region. Under ER stress, these CREB3 proteins are thought to be cleaved by the same regulated intramembrane proteolysis mechanism as ATF6, translocating into the nucleus and activating downstream target genes (33, 40, 52, 53, 62, 72) . They bind to various enhancer elements commonly found in the promoter region of UPR-related genes. All CREB3 proteins can activate transcription from CRE and UPRE (8, 11, 21, 33, 34, 44, 53, 57) . In addition, CREB-H/CREB3L1 and OASIS/ CREB3L3 bind box B and ERSE sequences (8, 33) , while Luman and CREB-H/CREB3L1 also bind ERSE-II (8, 40) .
Luman (44) was originally identified through its association with herpes simplex virus-related host cell factor 1 (HCF-1) (36, 83) . The mode of interaction between Luman and HCF-1 is mimicked by the herpes simplex virus type 1 protein VP16, which has led to the hypothesis that Luman may play a role in viral reactivation from latency (13, 42, 45) . Recently, the ERAD-related protein Herp (homocysteine-induced ER pro-tein) (32) or Mif1 (79) has been found to be a direct downstream target of Luman (40) . Luman induces cellular Herp expression during the UPR via transactivation of an ERSE-II enhancer element. Luman can also induce another ERAD protein, EDEM, likely through a UPRE-like element found in its promoter (11) . We have thus proposed that Luman may be a cross talk point between different signaling pathways of UPR and that Luman plays a unique role in ERAD that is fundamental to the herpes simplex virus lytic/latent replication cycle (40) . Recent data have also implicated Luman in human immunodeficiency virus replication (3) and monocyte cell migration (25) .
To investigate the cellular role of Luman and to identify cellular proteins that regulate its activation, we sought to identify cellular binding proteins of Luman using a yeast two-hybrid system. In this paper we report the discovery of a novel cellular protein, termed Luman/CREB3 recruitment factor (LRF). LRF is induced by ER stress and appears to be a negative regulator of the UPR. We found that LRF recruited the nuclear Luman protein to discrete foci in the nucleus and repressed Luman-mediated activation of UPRE-containing promoters.
MATERIALS AND METHODS
Yeast two-hybrid screening and isolation of LRF cDNA clone. The bait plasmid pGBKT7-LubZIP was constructed by PCR amplification from the plasmid pFLAG-Luman (also called pcLuman) (44) . The cDNA sequence coding for the leucine zipper domain of Luman (amino acids [aa] 162 to 228) was inserted into the pGBKT7 vector (Clontech) between the EcoRI-SalI sites. A pretransformed human fetal brain yeast two-hybrid library (MatchMakerIII; Clontech) was screened according to the manufacturer's instructions. Transformants were spread on a synthetic minimal dropout medium (0.67% [wt/vol] yeast nitrogen base, 2% [wt/vol] glucose, 2% [wt/vol] agar, and appropriate amino acids except leucine, tryptophan, histidine, and adenine) supplemented with 10 mM 3-amino-1,2,4-triazole to suppress background growth. Positive colonies were isolated, and the cDNA library plasmids were rescued. To confirm the interaction, the cDNA library plasmids were retransformed back into Saccharomyces cerevisiae cells with the bait or the empty vector (pGBKT7). Approximately 1 ϫ 10 6 independent colonies were screened, resulting in one positive clone that was selected for further analysis.
Cloning of full-length LRF gene by 5 rapid amplification of cDNA ends (RACE). First strand cDNA was synthesized from approximately 2 g of total RNA from HeLa cells, using the SuperScript II One-Step reverse transcription-PCR (RT-PCR) system (Invitrogen) according to the manufacturer's instructions. The full-length cDNA was subsequently amplified using the primers 5Ј-A GTGAATTCATGCCTCAGCCTAGTGTAAGC and5Ј-AATTCTCGAGTTA CACCTTTGATGTTGG (underlined sequences are restriction sites appended to the primers) and cloned into the vectors pEGFP-C2, pFLAG-C, and pM3 (containing the GAL4 DNA-binding domain; Ivan Sadowski, University of British Columbia) between the EcoRI/SalI sites. The resulting clones were confirmed by DNA sequencing.
Plasmids. The cDNA encoding N-terminal deletion mutants LRF consisting of amino acid residues 214 to 639 [LRF(214-639)], LRF(349-639), and LRF(451-639) and C-terminal mutants LRF(1-525) and LRF(1-347) were generated by PCR and cloned into the EcoRI/SalI site of the mammalian expression vector pHA-C that is modified from pcDNA3.1/myc-His (Invitrogen) to add the hemagglutinin (HA) epitope tag at the N terminus. Mutant LRF with a deletion of residues 415 to 519 (LRF⌬415-519) and LRF⌬488-504 were generated from the full-length pHA-LRF clone through site-directed mutagenesis using the QuikChange II system (Stratagene). The full-length LRF(1-639) cDNA was cloned into the bacterial expression vector pGEX-KG (coding for a glutathioneSepharose transferase fusion protein; Gerry Weinmaster, University of California, Los Angeles). The plasmid pIND-LRF was created by subcloning FLAG-LRF(1-639) into the HindIII/SalI site of the vector pIND (Invitrogen), which contains a ponasterone A-inducible promoter. Construction of pFLAG-Luman, pGEX-Luman, pM-Luman, pFLAG-Luman(1-215), and pGEX-Zhangfei (ZF) was described previously (45) . The plasmid p3ϫERSEII-Luc was created by cloning the linker 5Ј-AGCTTGCCGATTGGGCCACGTTGGGAGAGCCGATT GGGCCACGTTGGGAGAGCCGATTGGGCCACGTTGGGAGAA that contains three copies of the ERSE-II element into the HindII/BglII sites of the plasmid pGL3-promoter (Promega). The reporter plasmid p5ϫUPRE-Luc (gift from Ron Prywes, Columbia University) and p5ϫGAL4-Luc (Ivan Sadowski, University of British Columbia) contains five repeats of the UPRE sequence TGACGTG(G/A) or GAL4 upstream activation sequences, respectively, linked to the coding sequence for firefly (Photinus pyralis) luciferase. The pRL-SV40 (where SV40 is simian virus 40) plasmid (Promega) contains the Renilla (Renilla reniformis) luciferase gene under the control of the SV40 immediate-early promoter. The plasmids expressing the nuclear proteins pEGFP-SF2/ASF, pEGFP-RIP140, and pSG5-HA-GRIP1 (where EGFP is enhanced green fluorescent protein [GFP], RIP140 is nuclear receptor interacting protein 140, and GRIP1 is glucocorticoid receptor interacting protein 1) were generously provided by David Spector, Cold Spring Harbor Laboratories (27) , and LRF Ϫ/Ϫ mouse embryonic fibroblast (MEF) cells were grown in monolayer culture in Dulbecco's modified Eagle's medium (high glucose) supplemented with 10% (vol/vol) fetal bovine serum (Invitrogen), 100 IU/ml penicillin, and 100 g/ml streptomycin. All cultures were maintained in a 5% CO 2 humidified atmosphere at 37°C and passaged every 2 to 3 days. Cells were plated 24 h prior to transfection and allowed to grow to 50 to 60% confluence. Cells were transfected by Lipofectamine (Invitrogen) as previously described (44 Western blotting. Detection of LRF was performed using an affinity-purified rabbit polyclonal LRF antibody (RB37), raised against the peptide YENDSVE DLKEVTSISSRKR (custom made by Invitrogen). Other primary antibodies used include affinity-purified polyclonal Luman Rb5660 antibody described previously (40) , FLAG monoclonal antibody (M2; Sigma), and a ␤-actin monoclonal antibody (clone AC-15; Sigma). Blots were visualized using ECL Plus (GE Healthcare) on a Typhoon 9400 Phosphorimager (GE Healthcare).
RNA analysis. Total RNA was isolated with Trizol (Invitrogen) from cell cultures or adult mouse tissues. Synthesis of cDNA was performed using Superjected to standard curve analysis. Values were analyzed using the ABI 7300 System Sequence Detection Software, version 1.2.2, and are given relative to the wild-type untreated cells. To ensure that appropriate primer-specific products were produced, melting curve analyses were performed on the Sybr green channel using a ramping rate of 1°C/30 s for 60 to 95°C. Data are presented as the averages of three independent repeats.
Pulse-chase assay. At 20 h posttransfection cells were split equally into 6-mm plates and allowed to recover for 16 h. Cells were pulse-labeled in 35 S-labeled methionine-cysteine for 1 h and harvested at the indicated time points (see Fig.  5B and 6A). Lysates were immunoprecipitated with monoclonal FLAG antibody M2 (Sigma) and separated on a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel. Gels were dried, exposed to a storage phosphorous screen, and visualized on a Typhoon 9400 PhosphorImager.
Coimmunoprecipitation assay. LRF expression in EcR-293/LRF cells was induced with ponasterone A for 24 h with an 8-h treatment of MG132 and brefeldin A. Immunoprecipitations were performed using an M2 FLAG antibody and protein A beads. Western blotting analyses were performed using affinitypurified Luman RB5660 or LRF Rb37 antibody, as described above.
Dual luciferase assays. Cells were transfected as described above. At 16 h posttransfection, the medium was changed, and the cells were allowed to recover for 24 h. Cells were harvested and lysed, and dual luciferase assays were performed according to the manufacturer's protocols (Promega). Luciferase activity was measured using a Turner TD-20e Luminometer and calculated as relative luciferase activity (firefly luciferase/Renilla luciferase) to correct for transfection efficiency. Assays were independently repeated at least three times. Data are shown with standard errors.
GST pull-down assays. Glutathione S-transferase (GST) fusion proteins were produced in Escherichia coli strain BL21(DE3) (Novagen) and were purified using glutathione-Sepharose beads (GE Healthcare) (44, 45) . A rabbit reticulocyte in vitro transcription-translation system (TnT; Promega) was used according to the manufacturer's protocol to produce 35 S-labeled Luman, HCF-1, LRF and its mutants, and the GAL4 activation domain fused to GFP (as a negative control). Equal amounts of bead-bound proteins were used in all samples as determined by SDS-PAGE against bovine serum albumin standards. GST fusion proteins bound to glutathione-Sepharose 4B beads were incubated for 1 h with 15 l of in vitro 35 S-labeled protein in a total of 150 l of incubation buffer (140 mM NaCl, 50 mM Tris, pH 8.0, 2 mM Na 3 VO 4 , 5 mg/ml bovine serum albumin, and 0.5% [vol/vol] Igepal CA-630). Beads were collected by centrifugation, washed, and resuspended in 40 l of 2ϫ SDS sample buffer. The eluted protein was separated by SDS-PAGE and visualized on a Typhoon 9400 PhosphorImager.
Immunofluorescence confocal microscopy. Cells were fixed for 20 min in 4% paraformaldehyde, permeabilized for 5 min in 1% Triton X-100, and blocked for 60 min in 10% horse serum at room temperature. Primary antibodies were used at the following dilutions: Luman at 1:300, LRF at 1:150, HCF-1.2131 at 1:200, PML-PG-M3 at 1:200 (Santa Cruz), FLAG-M2 at 1:200 (Sigma), and HA-12CA5 at 1:200 (Roche). Secondary Alexa488-, Alexa546-, or Alexa633-conjugated antibodies were used at 1:400 (Invitrogen). Glass coverslips were incubated in antibodies for 60 min at 37°C with 5% CO 2 and were mounted in 50% glycerol with 500 pM DAPI (4Ј,6Ј-diamidino-2-phenylindole). Images were captured on a Leica DMRE confocal microscope. Figures were prepared using Adobe Creative Suite CS2.
Nucleotide sequence accession number. The nucleotide sequence of LRF cDNA has been deposited in the GenBank under accession number AY635785.
RESULTS
Identification of the LRF. Luman belongs to the CREB/ ATF family of transcription factors and contains a leucine zipper region which is a known protein dimerization motif (1). To identify cellular proteins that interact with Luman, the region (aa 162 to 228) containing the leucine zipper was used as bait in a yeast two-hybrid screen of a human brain cDNA library. Among approximately 1 ϫ 10 6 independent colonies that were screened, a single cDNA clone was obtained.
The isolated cDNA clone contained an insert of ϳ1.8 kb. BLAST (http: //www.ncbi.nlm.nih.gov/BLAST/) searches of the GenBank human cDNA database identified overlapping clones comprising a cDNA contig in which the largest open reading frame was 1,920 bp encoding a protein of 639 aa with a predicted molecular mass of 72 kDa. The presumed protein was designated LRF. The full-length open reading frame of LRF was subsequently cloned by 5Ј rapid amplification of cDNA ends using template RNAs extracted from HeLa cells. A more recent search of the GenBank human genome database correlated the open reading frame to a GenBank entry (GeneID 153222) that is predicted by a transcriptome analysis (74) to encode an adult retina protein with an unknown function.
LRF has been well conserved through evolution as it shares over 95% sequence identity at the amino acid level with mouse (GenBank GeneID 77128) and rat homologs (GenBank GeneID 303016) (Fig. 1) . The apparent structural features of the LRF proteins include a highly acidic region (aa 355 to 399), a typical bZIP region (aa 521 to 576) with a conserved 5-aa spacer between the basic region and the leucine zipper, and a second leucine zipper-like motif (aa 488 to 509) preceding the bZIP motif. In the acidic region, 33 out of the 45 amino acid residues are negatively charged glutamate or aspartate residues.
LRF interacts with Luman in vitro and in vivo. To verify the direct interaction between LRF and Luman, GST pull-down assays were performed. All proteins including two control proteins, HCF-1 and GAL4-GFP (GAL4 activation domain fused to GFP), LRF, and Luman were produced and 35 S labeled in rabbit reticulocytes. As shown in Fig. 2A , GST-Luman was able to pull down 35 S-labeled HCF-1 (the positive control, lane 4) as well as 35 S-LRF (lane 8) but not the negative control, 35 S-labeled GAL4-GFP (lane 12). It is known that bZIP proteins can heterodimerize with different bZIP proteins through the leucine-zipper motif. Since LRF was isolated through its interaction with the leucine zipper region of Luman, we asked whether LRF interacts with the leucine zipper of Luman in a specific manner. Therefore, in the same assay, we included ZF, a Luman-related HCF-1 binding protein, which also has a leucine zipper motif (43) . While ZF could complex with HCF-1 as expected, it did not bind LRF (Fig. 2A, compare lanes 3 and  7) . In a reciprocal GST pull-down assay (Fig. 2B) , LRF could pull down Luman efficiently and itself to a lesser degree but not the GAL4-GFP control. These results suggest that LRF interacts with Luman specifically.
To confirm this interaction in the mammalian cellular environment, we carried out a coimmunoprecipitation in EcR-293/ LRF cells in which FLAG-tagged LRF can be induced upon addition of ponasterone A to the medium. After a 24-hour induction, cultures were treated with brefeldin A to activate cellular Luman and induce its proteolytic cleavage (40, 62) , along with the proteasome inhibitor MG132 for 8 h. Cells were then harvested under nondenaturing conditions, and LRF complexes were precipitated with an anti-FLAG antibody. Only upon LRF induction was the endogenous nuclear form of Luman found in the LRF complex (Fig. 2C) .
LRF binds Luman through its C-terminal region. LRF was identified by virtue of its interaction with the leucine zipper region of Luman, which is a known dimerization domain for bZIP proteins. As LRF is also a bZIP protein, it is reasonable to speculate that LRF interacts with Luman through its bZIP domain. To map the region of LRF that is responsible for binding to Luman, a series of deletion mutants of LRF were made (Fig. 2D) . In GST pull-down assays using these LRF mutants, the C-terminal region (from aa 451 to 639) that has two leucine zipper-like sequences was sufficient for LRF to bind Luman (Fig. 2D, 4th row) . Removal of the C-terminal region (aa 348 to 639) containing both leucine zippers disrupted the interaction between LRF and Luman entirely. Deletion of the second leucine zipper in LRF(1-525) reduced LRF binding to Luman, while removal of the first leucine zipper (aa 488 to 504) abolished the interaction. From these results, we conclude that the first leucine zipper in LRF is indispensable, but both leucine zippers are required for optimal interaction between the two proteins.
LRF recruits Luman into nuclear foci in the cell. To investigate the cellular localization of the LRF protein, fluorescence confocal microscopy studies were carried out. A pEGFP-LRF plasmid expressing the GFP-LRF fusion protein was used to transfect 293 cells, along with plasmids expressing the fulllength Luman protein or the N-terminal portion (aa 1 to 215) of Luman. Interestingly, LRF was found exclusively in the nucleus in the form of discrete foci (Fig. 3A) .
To examine whether Luman colocalizes with LRF in these cells, 293 cells were cotransfected with pEGFP-LRF and pFLAG-Luman or pFLAG-Luman(1-215). The full-length Luman is a transmembrane protein associated with the ER, and the N-terminal region (aa 1 to 215) of Luman is believed to be the cleavage product and active form of Luman which is localized to the nucleus (40, 62) . In the cotransfected cells, the full-length Luman protein remained in the cytoplasm (Fig. 3 , compare rows B and D), while N-terminal Luman(1-215) was found to be recruited to the LRF nuclear bodies (Fig. 3 , compare rows C and E). Therefore, LRF was able not only to interact with Luman in vivo but also to recruit the nuclear Luman protein into the distinct subnuclear domains.
To investigate the identity of the LRF bodies, we first wanted to rule out that these LRF bodies are artifacts due to overexpression. We have tested different cell lines (e.g., 293, HeLa, and COS7) in our cell transfections, as well as various amounts of plasmid DNA and different expression constructs with weak promoters such as thymidine kinase from herpes simplex virus. LRF was found to form nuclear bodies under all the experimental conditions (date not shown). Next, we sought to compare LRF nuclear bodies to other known nuclear nodules/spots in the literature by confocal microscopy. In terms of morphology, these LRF nuclear bodies appeared to have welldefined and smooth edges. They are also much more spot-like compared to nuclear speckles, which are RNA processing centers (38) . The number of LRF bodies ranges from ϳ20 to ϳ200 per cell, depending on the cell type (data not shown), and they resemble the well-documented promyelocytic leukemia (PML) (95), and GRIP1/ TIF2 (transcriptional intermediary factor 2) bodies (30) . We found that LRF bodies did not colocalize with nuclear speckles but were juxtaposed with PML or RIP140 bodies. Strikingly, LRF and GRIP1 foci appeared to overlap perfectly (data not shown). These observations led us to conclude that the LRF nuclear bodies are a bona fide subnuclear domain, which is shared with GRIP1. Coexpression of LRF and Luman in animal tissues. Since LRF is a novel protein, we sought to characterize its tissue distribution; given that multiple human tissue samples are not readily available, we examined LRF expression by qRT-PCR in 10 mouse tissues analyses (adipose, brain, colon, heart, kidney, liver, lung, skeletal muscle, intestine, and testes) (Fig. 4A) . While LZIP (the Luman mouse homolog) and LRF coexist in many tissue types at the mRNA level, it appears that they have opposite expression levels when one of the two proteins is in extreme abundance. For instance, LRF is present at very high levels in heart and kidney tissues where Luman/LZIP is low, and the converse is true in the brain. These data seem to imply an antagonistic role of the two proteins.
As with Luman, attempts to survey LRF expression at the protein level in different cell types and tissues proved to be difficult. In our quest for endogenous LRF protein, numerous cell lines were examined. Only one cell line, rat C6 glial cells, has very recently been found to have an appreciable level of LRF by Western blotting using the proteasome inhibitor MG132 and concentrated cell lysates (Fig. 4B) . Interestingly, C6 is also the only known cell line that has a considerable amount of endogenous Luman/LZIP protein. We were thus interested in examining the subcellular localization of these two proteins. We found that Luman/LZIP was more readily detectable in all the cells by immunofluorescence microscopy, while LRF appeared to be concentrated in mitotic C6 cells. Surprisingly, we found that both proteins had punctate staining patterns in the mitotic cells. Although less distinct, these foci were very much reminiscent of the nuclear bodies of transfected LRF, especially those of LRF in mitotic C6 cells (Fig.  4B) .
Since Luman is known to be involved in the UPR and induced by ER stressors, we examined LRF induction by qRT-PCR in C6 cells under different ER stressor treatments. We found that LRF was induced by the same ER stressors as Luman/LZIP (Fig. 4C) .
LRF protein is tightly regulated by the proteasome. To investigate the stability of the LRF protein, we studied the effect of MG132 on the protein levels of transfected GFP-and FLAG-tagged LRF in 293 cells (Fig. 5A) . We found that although the levels of LRF mRNA expressed from the plasmids were similar (Fig. 5A, lower panel) , the LRF protein levels
FIG. 2. LRF interacts with Luman specifically through its C-terminal region. (A and B) GST pull-down assays. In vitro translated HCF-1, LRF, and GAL4-GFP were incubated with GST, GST-Luman, or GST-ZF(A) or GST-LRF (B) that were linked with glutathione beads.
35 S-labeled HCF-1 was used as a positive control, and 35 S-GAL4-GFP was used as a negative control. The binding reactions were subjected to SDS-PAGE and autoradiography. The input lanes have 10% of total 35 S-labeled proteins. (C) Immunoprecipitation assays. EcR-293/LRF cells were mock (Ϫ) or ponasterone A induced (ϩ), in addition to brefeldin A treatment. Precipitations were performed using the FLAG monoclonal antibody M2 and protein A beads. Western blotting analyses were carried out using antibodies, as indicated at the top of the figure. (D) Mapping of the Luman-binding region in LRF by GST pull-down assays. LRF and its mutants used in the assays are as illustrated in the diagram on the left. In the binding reactions, 35 S-labeled LRF was incubated with GST or GST-Luman glutathione beads. Ten percent of the input was included as a reference. were drastically different. Cells without MG132 treatment had substantially lower levels of LRF. Among them, FLAG-LRF cells without MG132 treatment completely failed to produce a band (Fig. 5A ). It appears that the addition of the larger GFP tag at the amino terminus stabilized LRF within the cell, compared to FLAG-LRF (Fig. 5A , compare lanes 3 and 4 with lanes 5 and 6). It was noted that, with a calculated molecular mass of 72 kDa, the apparent molecular masses of both FLAG-LRF and GFP-LRF were significantly larger, which we believe is likely due to posttranslational modifications of the protein.
To further quantify the stability of LRF protein, a pulsechase assay was performed on the FLAG-LRF protein. Following a 1-h pulse-labeling of transiently transfected cells, cultures were harvested at multiple time points up to 60 min. Cells were lysed in a nondenaturing buffer and immunoprecipitated with an anti-FLAG antibody. After precipitation, SDS-PAGE, and autoradiography, a single band was found for LRF in each sample (Fig. 5B) . The intensity levels of the bands were quantified on a phosphorimager and standardized to the intensity of the time zero sample. Analysis revealed that the half-life of LRF was less than 20 min. In the controls of MG132-treated cells, the half-life of the protein was greater than 60 min, or FIG. 3 . Confocal microscopic analysis of LRF subcellular localization and its interaction with Luman. 293 cells were either transfected separately with plasmids pEGFP-LRF (A), FLAG-Luman (B), and FLAG-Luman(1-215) (C) or cotransfected with pEGFP-LRF and FLAGLuman (D) or pEGFP-LRF and FLAG-Luman(1-215) (E). FLAG-Luman proteins were visualized by immunofluorescence labeling using the anti-FLAG monoclonal antibody M2 (Sigma). LRF is shown in green, and the Luman proteins are in red. Images from the green, red, and differential interference contrast channels of the same optical field were captured with a Hamamatsu ORCA-ER digital camera under a Leica DMRE confocal microscope. Composite images of the two channels are shown in the third column. Together, these results demonstrate that the LRF protein is prone to proteasome degradation and that stability is an important regulatory mechanism of LRF in the cell. LRF promotes Luman protein degradation. To investigate whether LRF recruitment of the nuclear form of Luman into the LRF foci also impacts the stability of the Luman protein, we cotransfected 293 cells with plasmids expressing the N-terminal Luman(1-215) and LRF or a Luman-binding mutant LRF⌬415-519 and examined the half-life of Luman by pulse-chase assays. We found that the turnover of Luman was more than three times faster when Luman was cotransfected with the full-length LRF than when the blank vector or LRF mutant controls were used (Fig. 6A ). The fact that the level of Luman mRNA was not affected by LRF cotransfection (Fig. 6B) suggests that reduction of the Luman protein level was not due to transcriptional repression. In agreement with these results, we noticed that while Luman was readily induced (Fig. 4C ) and proteolytically cleaved in cells treated with thapsigargin as detected by Western blotting (40) , there was significantly less Luman/LZIP protein in the nucleus of thapsigargintreated C6 cells visualized by immunofluorescence microscopy (Fig. 6C) . Furthermore, when the full-length LRF, but (Fig. 6C) . LRF represses the activity of Luman during the UPR. To study the functional relevance of the LRF-Luman interaction, we sought to analyze the impact of LRF on the transcription activation function of Luman. Previous studies (11, 40) suggest that Luman may play a role in the ERAD pathway during the UPR and can activate enhancer elements, UPRE and ERSE-II. To analyze the effect of LRF on the Luman response to ER stress, the pcLuman plasmid was used to transfect 293 cells along with a plasmid expressing LRF or the Luman-binding mutant. Using a 5ϫUPRE luciferase reporter, we found that LRF, but not LRF⌬415-519, could modestly but reproducibly repress the transactivation potential of Luman by 35% (Fig.  7A) . A similar level of inhibition was seen when Luman expression was coupled with thapsigargin treatment. Western blot analysis showed that Luman protein levels appeared consistent in the presence and absence of LRF. It should be noted that since Western blotting displays only steady-state protein levels, we cannot rule out the possibility that the observed repression was due to LRF-induced rapid turnover of the Luman protein. Due to the fact that the LRF protein cannot be detected in the absence of MG132, semiquantitative RT-PCR was used to confirm the consistency of LRF levels in all the transfected samples (Fig. 7A, lower panel) . When the ERSE-II reporter was examined, however, the LRF repression of the activity of Luman was not significant (Fig. 7B) . We postulate that other ERSE-II-activating cellular factors in 293 cells might have masked the repression effect of LRF. To eliminate background activation and check the potential promoter specificity of the LRF repression, the GAL4 upstream activation sequence reporter system was also tested. We found that the transcription potential of Luman was reduced by ϳ45% by LRF overexpression (Fig. 7C) . Thus, the LRF repression of Luman transactivation potential appears to be independent of the promoter context.
To further examine the repressive effect of LRF, thapsigargininduced activation of UPRE and ERSE-II were examined in LRF wild-type and null MEF cells. Higher levels of reporter activities were seen with both UPRE (150%) and ESRE-II (128%) in LRF Ϫ/Ϫ cells than in LRF ϩ/ϩ cells ( Fig. 7D and E ). The two reporters had even greater activity increases in untreated MEF cells, which could be explained by the masking effect of other cellular factors induced by thapsigargin.
LRF is a negative regulator of the mammalian UPR. Next, we sought to study the possible function of LRF in the mammalian UPR using the LRF ϩ/ϩ and LRF Ϫ/Ϫ MEF cells. A time course survey by qRT-PCR indicated that LRF was continuously induced in LRF ϩ/ϩ cells under thapsigargin treatment even though cells started to die after 8 h (Fig. 8A) . As expected, no LRF mRNA was detected in LRF Ϫ/Ϫ samples. We therefore chose the 8-h thapsigargin treatment as the time point and evaluated transcriptional induction of key UPR genes, ATF4, CHOP, EDEM, GRP78, Herp, and XBP1 (Fig.  8B) . Out of the six genes examined, CHOP (22%), EDEM (35%), and Herp (32%) showed significant increases in thapsigargin-induced activation in LRF Ϫ/Ϫ cells, of which EDEM and Herp are known downstream targets of Luman (11, 40) and are believed to play a role in ERAD. Notably, induction of the key ER chaperones GRP78, ATF4, and XBP1 was not affected by LRF deficiency. Thus, the enhancement of EDEM and Herp transcription may be the outcome of the alleviation of LRF repression on endogenous Luman/LZIP in the LRF Ϫ/Ϫ cells that led to augmentation of its downstream gene expression.
Exclusion of HCF-1 from LRF nuclear bodies. Since Luman is also known to interact with HCF-1, we were interested to investigate whether LRF can also recruit HCF-1 into the discrete nuclear foci along with Luman. We transfected 293 cells with pEGFP-LRF or pFLAG-Luman(1-215) alone or cotrans- RT-PCR analysis was done using primers specific to the transfected exogenous LRF or endogenous actin. (B) Pulse-chase analysis was performed with pFLAG-LRF transiently transfected 293 cells. Transfected cells were either mock or MG132 (5 M) treated for 8 h prior to a 1-h pulse-labeling with 35 S-labeled methionine-cysteine. Lysates were harvested at 0, 10, 20, 30, 45, and 60 min for untreated samples (blank) and at 0, 30, and 60 min in MG132-treated samples. Lysates were immunoprecipitated with monoclonal FLAG antibody M2 (Sigma) and separated on a 12% SDS-PAGE gel. Images were acquired using a Typhoon 9400 PhosphorImager. Band intensities were analyzed using ImageQuant and expressed as relative abundance compared to time zero values. Data are representative of two independent trials and plotted with standard errors.
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on February 23, 2013 by PENN STATE UNIV http://mcb.asm.org/ fected the cells with both plasmids and checked the subcellular localization of endogenous HCF-1. Immunofluorescence confocal microscopy showed that LRF did not colocalize with HCF-1 in the absence (Fig. 9, I ) or the presence of Luman (Fig. 9, III) . Although the N-terminal Luman colocalized with HCF-1 almost perfectly without LRF (Fig. 9, II) , upon transfection of LRF, Luman was recruited to the LRF nuclear bodies while HCF-1 was not (Fig. 9, III) . A closer examination of the confocal microscopic images revealed that the majority of HCF-1 appeared to be excluded from the LRF bodies (Fig.  9 , insets in I and III).
DISCUSSION
In this study we report the discovery of a novel cellular protein, LRF, that interacts with the transcription factor Luman (13, 42, (44) (45) (46) (47) . Our data suggest that LRF is a negative regulator in the mammalian UPR, especially in the EDEMand Herp-related ERAD pathway. LRF not only promotes Luman protein degradation through direct binding but also recruits the nuclear Luman protein to discrete nuclear foci and represses its transactivation potential. In addition to accelerating Luman turnover, a key mechanism of LRF repression may be sequestration of Luman in LRF nuclear bodies, thereby excluding cofactors, such as HCF-1, that are required for Luman transactivation. We thus believe that LRF represents another level of control of Luman after its proteolytic cleavage and translocation to the nucleus.
LRF is predicted to be a protein of 639 aa that is extremely well conserved in humans and rodents (Fig. 1) . This high level of conservation during the course of evolution suggests a critical cellular role for LRF. Similar to Luman (40) , the level of LRF in the cells appears to be tightly regulated by proteasomes, since the proteasome inhibitor MG132 significantly improved the stability of the protein (Fig. 5) . The very short half-life of LRF (ϳ20 min) agrees with the observation that the LRF protein is normally present at very low levels, if at all, in most cell types. Not surprisingly, LRF also promotes degradation of Luman (Fig. 6) , which may be one of the mechanisms of LRF negative regulation of Luman. It is worth noting that, in this regard, LRF is very much reminiscent of XBP1u in its relation to XBP1s. Like LRF, the unstable protein XBP1u selectively binds XBP1s through the leucine zipper motif and represses the transactivation activity of XBP1s by accelerating its proteasomal degradation (94) .
It is now being increasingly appreciated that the cellular nucleus is functionally compartmentalized and that proteins are targeted to discrete subdomains within the nucleus to per- form specialized functions. The LRF nuclear bodies appear to be different from other commonly known subnuclear structures, including nucleoli, nuclear speckles, paraspeckles, cajal bodies, gems, and PML/ND10 bodies. These nuclear bodies, although not bound by membranes, form distinct compartments within the nucleus and contain sets of proteins with specialized functions, such as DNA replication and repair, transcription, RNA processing, gene silencing, and protein degradation (reviewed in references 9, 10, 37, 38, and 96). In relation to other well-documented nuclear foci, LRF nuclear bodies do not resemble nuclear speckles. The apparent juxtaposition of LRF with PML/ND10 and RIP140 may suggest that they are all tethered to an unknown structure in the nucleus. The discovery of the perfect colocalization of LRF with GRIP1 in the nuclear foci (data not shown) may be of particular importance since GRIP1 is a known nuclear receptor (NR) coactivator (22, 81) . One of the hallmarks of NR coactivators is the presence of the NR box, a stretch of amino acids with the sequence LXXLL, where X represents any amino acid. Sequence analysis failed to identify any putative NR boxes within LRF; however, Luman is known to possess two LXXLL motifs in its N terminus. It has been demonstrated that these regions are important to the activation potential of Luman when fused to the GAL4 DNA-binding domain (47) . Perhaps recruitment of Luman to these LRF nuclear bodies may not only repress the transactivation function of Luman but It is worth noting that, through our persistent effort, both endogenous LRF and Luman/LZIP were found in C6 rat glial cells (Fig. 4B) . The punctate staining patterns of both proteins in mitotic cells during metaphase were especially encouraging.
Unfortunately, we could not reliably determine whether the LRF and Luman/LZIP proteins colocalized in C6 cells, since all our LRF and Luman/LZIP antibodies have the same host origin. At metaphase of the cell cycle, nuclear envelope is already dissolved. It is thus possible for the nonproteolytically processed Luman to interact with LRF. It should also be pointed out, however, that Luman may not be localized in LRF bodies under the "normal" conditions. We noticed that the level of LRF was still very low in the C6 cells (estimated to be 10-fold lower than Luman/LZIP). This might explain why these endogenous LRF nuclear bodies were not as distinct as those in transfected cells. It is possible that LRF forms visible nuclear bodies only under certain cellular conditions when the level of LRF protein reaches a threshold. Luman as a transcription factor is normally bound to the ER through a C-terminal transmembrane domain, with all the known functional domains facing the cytosol. During the UPR, Luman is believed to be cleaved by regulated intramembrane proteolysis (40, 62) , and the N-terminal Luman translocates to the nucleus, turning on downstream targets. Therefore, recruitment of nuclear Luman into specific subnuclear domains by LRF should represent another level of regulation for Luman, subsequent to the proteolysis event in the cytoplasm. Although both LRF and HCF-1 are proteins that interact with Luman in the nucleus, they are potentially two antagonizing forces that regulate the function of Luman, with HCF-1 being the positive cofactor promoting transcription activation by Luman and LRF being a repressor. With current data suggesting that HCF-1 is a ubiquitous cell cycle regulator (28, 31, 77) , LRF is more likely to provide tissue specificity that fine-tunes the activity of Luman.
As a working model for the function of Luman recruitment into LRF nuclear bodies, we propose that once proteolytically FIG. 9 . Exclusion of HCF-1 in the LRF nuclear bodies in the presence or absence of Luman. The 293 cells were either transfected separately with pEGFP-LRF (I) or pFLAG-Luman(1-215) alone (II) or with both plasmids (III). FLAG-Luman(1-215) was visualized using M2 (Sigma) monoclonal antibody against FLAG, while endogenous HCF-1 was detected by polyclonal antibody 2131 (36) . The displayed images in each set are captured from multiple channels of the same optical field. Inset images of I and III show regions at higher magnification. processed Luman translocates to the nucleus, it may first associate with HCF-1 and form a transcription activation complex, turning on downstream target genes such as ER stressrelated Herp and EDEM (11, 40) (Fig. 10) . At a certain point of the UPR where the cellular environment changes and the level of LRF in the nucleus rises to a threshold, Luman may be recruited into the LRF nuclear bodies. Translocation of Luman into these LRF nuclear bodies represses its transactivation potential, possibly by sequestering it from essential cofactors (such as HCF-1) and by promoting Luman protein degradation by the proteasome. After the cellular response is near completion, both LRF and Luman may be rapidly degraded. With the availability of a newly established LRF gene knockout mouse line, this hypothesis is being tested. 
